... Sotorasib (Lumakras) EGFR inhibitors Afatinib (Gilotrif) Amivantamab (Rybrevant) Dacomitinib (Vizimpro) Erlotinib (Tarceva) Gefitinib (Iressa) Lazertinib (Lazcluze) Necitumumab (Portrazza) Osimertinib (Tagresso) Sunvozertinib (Zegfrovy) ALK inhibitors Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Ensartinib (Ensacove ...
NSCLC Targeted Therapy: 8 Facts
... Sotorasib (Lumakras) EGFR inhibitors Afatinib (Gilotrif) Amivantamab (Rybrevant) Dacomitinib (Vizimpro) Erlotinib (Tarceva) Gefitinib (Iressa) Lazertinib (Lazcluze) Necitumumab (Portrazza) Osimertinib (Tagresso) Sunvozertinib (Zegfrovy) ALK inhibitors Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Ensartinib (Ensacove ...
... Several TKIs have been developed to stop ALK from signaling cells to grow and divide, including: Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Ensartinib (Ensacove) Lorlatinib (Lorbrena) More ALK inhibitors are in the pipeline. ...
How Does Targeted Therapy for Lung Cancer Work?
... Several TKIs have been developed to stop ALK from signaling cells to grow and divide, including: Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Ensartinib (Ensacove) Lorlatinib (Lorbrena) More ALK inhibitors are in the pipeline. ...
... Small-molecule inhibitors that treat ALK mutations include: Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Ensartinib (Ensacove) Lorlatinib (Lorbrena) ROS1 InhibitorsROS1 gene rearrangements can occur similarly to those seen with the ALK gene and can sometimes be treated with the same targeted therapies. ...
Lung Cancer Treatment Options
... Small-molecule inhibitors that treat ALK mutations include: Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Ensartinib (Ensacove) Lorlatinib (Lorbrena) ROS1 InhibitorsROS1 gene rearrangements can occur similarly to those seen with the ALK gene and can sometimes be treated with the same targeted therapies. ...
... Some of the latest ones include: Ensartinib (Ensacove) — Approved in 2024 for people with ALK-positive advanced or metastatic NSCLC Lazertinib (Lazcluze) — Approved in 2024 for people with advanced or metastatic NSCLC with certain EGFR mutations Taletrectinib (Ibtrozi) — Approved in 2025 for adults with locally advanced or metastatic NSCLC that tests ...
NSCLC: Advances in Diagnosis, Staging, and Metastatic Therapies (VIDEO)
... Some of the latest ones include: Ensartinib (Ensacove) — Approved in 2024 for people with ALK-positive advanced or metastatic NSCLC Lazertinib (Lazcluze) — Approved in 2024 for people with advanced or metastatic NSCLC with certain EGFR mutations Taletrectinib (Ibtrozi) — Approved in 2025 for adults with locally advanced or metastatic NSCLC that tests ...
Join
